Professional Media briefs: October 2013

Professional Media briefs: October 2013
Professional Media briefs: October 2013

Wolters Kluwer launched the healthcare industry's first electronic nurses references focusing solely on oncology and psychiatric drugs. The company designed the two new apps, which are subsets of the larger Nursing Drug Handbook, for iPhones, iPad and the iPod Touch. The oncology app lists 169 antineoplastic drugs and the psychiatry app has 240 drugs that treat disorders and conditions, making it easier to hone in on the almost 4,000 drugs that are addressed in the Nursing Drug Handbook.

John Wiley & Sons and the American Neurological Association are launching a new online open-access journal, Annals of Clinical and Translational Neurology, with John “Jack” Kessler as Editor-in-Chief. The launch deepens a relationship that dates to 2001 when Wiley started publishing the organization's Annals of Neurology. Articles will be published under a ­Creative Commons license.

The Association of Health Care Journalists named its 2013-2015 board of directors. Some picks: the Philadelphia Inquirer's Karl Stark as president, MedPage Today's Ivan Oransky as VP, the Providence Journal's Felice Freyer as treasurer and Kaiser Health News's Julie Appleby as secretary.
You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.